Compare PRTS & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRTS | TIL |
|---|---|---|
| Founded | 1995 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.7M | 48.4M |
| IPO Year | 2006 | 2021 |
| Metric | PRTS | TIL |
|---|---|---|
| Price | $6.30 | $7.35 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $0.50 | ★ $125.00 |
| AVG Volume (30 Days) | ★ 22.3K | 7.7K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.06 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.25 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.37 | $5.67 |
| 52 Week High | $7.27 | $33.83 |
| Indicator | PRTS | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 58.57 | 46.10 |
| Support Level | $5.91 | $6.91 |
| Resistance Level | $6.61 | $7.50 |
| Average True Range (ATR) | 0.38 | 0.19 |
| MACD | 0.11 | 0.03 |
| Stochastic Oscillator | 69.46 | 62.63 |
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. It serves as an end-to-end solution for automotive repair and maintenance resources, offering a seamless online shopping experience that empowers drivers along every part of their journey. The company principally sells its products to individual consumers through its network of websites and online marketplaces. Its products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.